# Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

> **NCT05263921** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir

## Key facts

- **NCT ID:** NCT05263921
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263921, "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05263921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*